Their germline mutations and, consequently, loss of function were associated with the higher risk of breast (ranging from 57% in BRCA1 mutation to 45% in BRCA2 mutation) and ovarian cancers (ranging from 11% in BRCA1 mutation to 40% in BRCA2 mutation) [96]. The gene discussed is BRCA2; the disease is ovarian carcinoma.